Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol 2021 Nov;195(3):429-432

Date

07/14/2021

Pubmed ID

34254289

Pubmed Central ID

PMC9293486

DOI

10.1111/bjh.17700

Scopus ID

2-s2.0-85109689194   1 Citation

Abstract

Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.

Author List

Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M

Authors

Sameem Abedin MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Acute Disease
Adult
Aged
Allografts
Bone Marrow Transplantation
Cord Blood Stem Cell Transplantation
Drug Resistance
Female
Graft vs Host Disease
Humans
Immunosuppressive Agents
Male
Middle Aged
Nitriles
Peripheral Blood Stem Cell Transplantation
Pyrazoles
Pyrimidines
Retrospective Studies
Salvage Therapy
Young Adult